In summary, the aim of this study was to investigate the role and potential mechanisms of a PFKFB3 small molecule inhibitor loaded in cell membrane nanovesicles in improving glucose metabolism disorders following AP by integrating systematic bioinformatics analysis and nanovesicle drug delivery technology. This evidence concerns the gene PFKFB3 and alkaline phosphatase measurement.